From the Therapeutic Goods Administration (TGA)
TGA Business Plan 2022-23
The Therapeutic Goods Administration (TGA) has released a new Business Plan 2022-23. The Plan sets out product regulation, stakeholder engagement, regulatory compliance and innovation agenda for 2022-23 listing activities they will undertake to achieve these objectives.
In the Message from Deputy Secretary, Adjunct Prof John Skerritt states:
‘In 2022-23, we will continue to increase our engagement with patients, consumers, industry and health professionals by strengthening relationships with representative bodies, organisations and individuals. Our risk-based compliance and enforcement activities will be essential in maintaining the quality, safety and efficacy of therapeutic goods and maintaining confidence in these products.
We will continue our leadership role in international collaboration to build a more globally aligned regulatory framework and collaborate on joint evaluations of a large number of products. The TGA’s International Engagement Strategy 2021-2025 describes how we work with our international regulatory counterparts as well as our important work in the Asia Pacific region.
This Business Plan sets out our product regulation, stakeholder engagement, and compliance and innovation agenda for 2022–23. It supplements the broader Department’s Portfolio Budget Statements and Corporate Plan’.
The TGA, as part of the Australian Government Department of Health, is responsible for enabling therapeutic goods available for supply in Australia to be safe and fit for their intended purpose. These include goods Australians rely on every day, such as analgesics and sunscreens, through to goods used to treat and prevent serious conditions, such as prescription medicines, vaccines, blood products and surgical implants.
‘The TGA Business Plan provides details on our key deliverables in relation to the regulation of therapeutic goods, and should be read in concert with our performance reporting.’